RECURRENT MYCOSIS FUNGOIDES
Clinical trials for RECURRENT MYCOSIS FUNGOIDES explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MYCOSIS FUNGOIDES trials appear
Sign up with your email to follow new studies for RECURRENT MYCOSIS FUNGOIDES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Immune-Targeting drug tested for Tough-to-Treat blood cancers
Disease control OngoingThis is an early-stage study to find the safest dose of an experimental immunotherapy drug called MEDI-570. It is for adults with specific types of advanced T-cell lymphoma that have come back or stopped responding to previous treatments. The main goals are to check for side effe…
Matched conditions: RECURRENT MYCOSIS FUNGOIDES
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug duo tested to fight aggressive blood cancer
Disease control OngoingThis study is testing a combination of two drugs, pembrolizumab and romidepsin, for people with a type of blood cancer called peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if using these drugs together is safe and mor…
Matched conditions: RECURRENT MYCOSIS FUNGOIDES
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for patients with aggressive lymphoma that Won't respond
Disease control OngoingThis study is testing two drugs, durvalumab and lenalidomide, to see if they can help control advanced T-cell lymphomas that have come back or stopped responding to other treatments. It aims to find the safest dose and see how well the drugs work, either alone or together, for pa…
Matched conditions: RECURRENT MYCOSIS FUNGOIDES
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC